Fate Therapeutics (FATE) to Release Earnings on Thursday

Fate Therapeutics (NASDAQ:FATE - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Fate Therapeutics to post earnings of ($0.39) per share and revenue of $1.18 million for the quarter.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The firm had revenue of $1.86 million for the quarter, compared to analyst estimates of $1.57 million. On average, analysts expect Fate Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fate Therapeutics Stock Up 5.6 %

NASDAQ FATE traded up $0.07 on Friday, hitting $1.31. 1,369,266 shares of the stock were exchanged, compared to its average volume of 2,271,627. Fate Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $5.92. The company has a 50-day moving average price of $1.01 and a 200-day moving average price of $1.64. The company has a market cap of $150.13 million, a PE ratio of -0.79 and a beta of 2.31.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wedbush reaffirmed a "neutral" rating and set a $5.00 price target on shares of Fate Therapeutics in a report on Thursday, March 6th. Stifel Nicolaus decreased their price target on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating for the company in a research note on Thursday, March 6th. StockNews.com cut Fate Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a report on Thursday, March 6th. Finally, Wells Fargo & Company cut their target price on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $5.43.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.